{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    9,
    10,
    11,
    13,
    16,
    17,
    18,
    22,
    23,
    29,
    44,
    47,
    49,
    50
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Trial Flow Chart Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.0",
        "sectionTitle": "TRIAL FLOW CHART",
        "description": "Reference for specific procedures and visit windows"
      },
      {
        "id": "ref_2",
        "name": "Trial Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.0",
        "sectionTitle": "TRIAL PROCEDURES",
        "description": "Reference for details of each clinical procedure"
      },
      {
        "id": "ref_3",
        "name": "Stratification Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.4",
        "sectionTitle": "Stratification",
        "description": "Reference for subject stratification by histology and region"
      },
      {
        "id": "ref_4",
        "name": "irRECIST Methodology Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.1.4.1.5",
        "sectionTitle": "immune-related RECIST (irRECIST)",
        "description": "Reference for the adaptation of RECIST 1.1 for immunotherapy"
      },
      {
        "id": "ref_5",
        "name": "Interim Analysis Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.7",
        "sectionTitle": "Statistical Analysis Plan",
        "description": "Reference for formal interim efficacy analysis details"
      },
      {
        "id": "ref_6",
        "name": "Abbreviations Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "12.7",
        "sectionTitle": "Abbreviations",
        "description": "Reference for the list of abbreviations used in the document"
      },
      {
        "id": "ref_7",
        "name": "Toxicity Grading Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "12.6",
        "sectionTitle": "NCI CTCAE",
        "description": "Reference for CTCAE version 4.0 toxicity definitions"
      },
      {
        "id": "ref_8",
        "name": "Dose Modification Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2.1",
        "sectionTitle": "Dose Selection/Modification",
        "description": "Reference for dose modification guidelines"
      },
      {
        "id": "ref_9",
        "name": "Blinding Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.1.5.2",
        "sectionTitle": "Blinding/Unblinding",
        "description": "Reference for unblinding methods during the trial"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "In cases of anaphylaxis, epinephrine should be used immediately.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 4: Pembrolizumab Infusion Reaction Dose modification",
        "pageNumber": 45
      },
      {
        "id": "annot_2",
        "text": "Any COVID-19 vaccine that is licensed in a given country is allowed in the study.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "5.5.2 Prohibited Concomitant Medication",
        "pageNumber": 14
      },
      {
        "id": "annot_3",
        "text": "If after the evaluation the event is determined not to be related to pembrolizumab, the investigator does not need to follow the treatment guidance.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Supportive Care Guidelines for Pembrolizumab",
        "pageNumber": 50
      },
      {
        "id": "annot_4",
        "text": "Siewert type I tumors are adenocarcinomas of the lower esophagus with the center located within 1cm to 5cm above the anatomic EGJ.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "2.0 Trial Design",
        "pageNumber": 17
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "181-06",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-06-25",
        "description": "Update dose modification/toxicity guidelines for irAEs and clarify COVID-19 vaccine use.",
        "amendmentNumber": "Amendment 6"
      },
      {
        "id": "ver_2",
        "versionNumber": "181-05",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2018-03-08",
        "description": "Alpha spending function update and replacement of stratified log-rank test with max-combo test.",
        "amendmentNumber": "Amendment 5"
      },
      {
        "id": "ver_3",
        "versionNumber": "181-04",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-08-03",
        "description": "Primary objectives changed from dual endpoints (OS/PFS) to single endpoint (OS).",
        "amendmentNumber": "Amendment 4"
      }
    ],
    "summary": {
      "referenceCount": 9,
      "annotationCount": 4,
      "versionCount": 3
    }
  }
}